http://www.reliablebiopharm.com
Reliable Biopharmaceutical Corporation was recently awarded the highly coveted Lilly Global Supplier of the year. This award recognizes those companies who continually help create and sustain Lilly's competitive edge. In the second year of nomination, Reliable Biopharmaceutical earned this honor received by only .02 percent of all Lilly suppliers. Reliable's dedication to on time deliveries and quality product manufacturing has earned them this distinguished honor. Founded in 1968, Reliable Biopharmaceutical Corporation has evolved from a chemical manufacturing plant to a leader in the purified processing chemicals and Active Pharmaceutical Ingredient (API) manufacturer holding eleven active Drug Master Files (DMFs) with more in development. Initial successes with Small Business Innovation Research grants from the National Institutes of Health, including the prestigious Tibbetts Award in 1997, laid the technical foundation that defines Reliable Biopharmaceutical Corporation as a company. Reliable Biopharmaceutical Corporation manufactures Active Product Ingredients (API's) for many FDA regulated industries including the parental pharmaceutical, generic pharmaceutical, and cosmetic industries. Also manufactured are intermediate products and highly purified processing chemicals such as enzymes, buffers, and excipients that are used in the finished drug process or the finished drug form. Among these purified processing chemicals are Urea Ultra Pure, Sodium Dedicyl Sulfate- High Purity, Purified Phenol Liquefied, Carboxypeptidase B, and Lactobionic Acid. The fully audited and cGMP facility is located in St Louis, Missouri and has had many years of strong growth by continuing to be a leader in innovation and purification with customers around the world. Reliable recently commissioned a new high containment suite for the manufacture of potent compounds and significantly increased their headcount to support their future direction.
TEVA UK Limited package and market one of the widest ranges of generic products in the UK . We offer generic products in all major therapeutic areas in a variety of dosage forms, from tablets and capsules to ointments, creams, liquids and injectables. From our headquarters in Morley near Leeds, we deliver direct to customers through our wholesaler partners. Since 1998, our Hampden Park facility in Eastbourne has been a Centre of Excellence for Packaging. The investment in this Centre allowed us to be the first generic supplier to convert our range into patient packs. The logic behind this expanding range of products and pack sizes allows us to meet the needs of all our customers: from community pharmacists and dispensing doctors to hospital pharmacies. It gives you a single authoritative and well resourced source for the vast majority of your generics needs. Having the resources of TEVA behind us mean we are well placed to add to this range on day one after the expiry of major patents. TEVA Pharmaceuticals has a unique degree of back integration, manufacturing many of the Active Pharmaceutical Ingredients in our generic products. So whilst our range and packaging choices continue to grow, we're able to keep a firm control over the quality, availability and cost of every generic product we market.
Phyto-Riker Pharmaceuticals' product offerings include anti-allergy, anti-infectious, anti-malarial, analgesics, and psychotherapeutic drugs, gastro-intestinal agents, and vitamins. In addition, PRP has positioned itself to become a pioneer in the commercial development of African herbal products, traditional medicines, and modern derivatives thereof for sale in Ghana, other African countries, and international markets. PRP has successfully registered 24 products in 18 African countries to date, demonstrating its ability to do so consistently and providing additional validation of its quality standards. Nearly all products are marketed under the branded generic name of "Phyto-Riker". PRP has established a network of leading wholesale customers and sales representatives in the Anglophone and Francophone West African markets. PRP sells to both private distributors (about 75%) and public sector clients. It has won government tenders to date in Ivory Coast, Mali, Senegal, Gabon, Benin, and Ghana. PRP has strong relationships with suppliers of high quality raw materials and finished products in Asia and Europe. Since most of the inputs come from large manufacturers in India and China, PRP's cost basis and selling prices are competitive vis-Ã -vis other suppliers in Africa who also source their products in Asia. PRP expects to gain a pricing edge as its volume of business increases as closer strategic relationships are developed with select suppliers. The company enjoys Export Free Processing Zone (EPZ) status in Ghana and holds an ECOWAS license, offering the company the streamlined customs procedures and duty reductions available to West African firms engaged in intra-regional trade among the ECOWAS member states in West Africa.
Interpharm manufactures 100% of their products on-site, thus assuring control and conformance to Interpharm's high quality and standards. The products include tablets, capsules and packages in multiple-unit containers, screw capped bottles and bulk pouches. In addition to Interpharm's core customer base that buys Interpharm's products directly, there is also a growing segment of private label customers, as well as bulk finished product repackagers. The plant layout provides separate areas for receiving, quarantined components, released components, manufacturing, packaging, warehousing and QA/QC testing. The typical process flow, where applicable, is as follows: All manufacturing and packaging equipment is constructed of high quality pharmaceutical grade materials and are designed to facilitate cleaning, maintenance and optimum performance. The Quality Control Laboratory utilizes current methods of analysis and state of the art instrumentation to test and evaluate incoming components, in-process and finished products in accordance with customer, FDA and cGMP requirements. The laboratory also oversees a modern, large-scale product stability and retention program not only for the purpose of regulatory compliance but also for ongoing quality monitoring and continuous improvement of products.
MedPharm provides a full range of pharmaceuticals, diagnostic equipment and water treatment systems to NGOs and UN organizations operating in areas of conflict and in post-war relief and reconstruction activities such as those in Afghanistan , Palestine , Philippines and Iraq . In response to the Tsunami disaster of December 2004, MedPharm in cooperation with its NGO clients, the UN and the DOD, provided pharmaceuticals, diagnostic equipment and water treatment systems in numerous airlift shipments to India , Sri Lanka and Indonesia. Through its subsidiary, MedPharm Europe, MedPharm contract manufactures key essential drugs in Europe under the MedPharm label. It also procures and supplies over 300 generic drugs from leading European manufacturers, including all the drugs listed on the WHO Essential Drugs List. MedPharm, working with its Dutch partner, has the strategic advantage of a new pharmaceutical consolidation facility in Holland with state-of-the-art equipment to assure quality control. Here several hundred pharmaceutical products and medical supplies are consolidated, stored and packaged for export. The pharmaceutical products from Europe meet full GMP and international quality standards (USP, BP, and EP Pharmacopoeia). All pharmaceuticals are fresh stock with full shelf life (18 months to 4 years until expiry date).
Dexcel markets over 65 products in more than 170 dosages, principally in solid oral dosage form (see "Products"). In the generic pharmaceuticals market, Dexcel primarily focuses its efforts on selected controlled-release generic versions of brand name pharmaceuticals, mostly under its own patented technologies. Dexcel also develops generic pharmaceuticals that present one or more competitive barriers to market entry, such as complex formulation or development characteristics, or special manufacturing requirements. In the branded pharmaceuticals market, Dexcel's branded products portfolio consists of products to which Dexcel has applied its formulation expertise to develop differentiated, modified, or controlled-release versions of currently marketed drugs.Sales & marketing: Dexcel's innovative pharmaceutical products are commercialized directly through its own sales force, through co-promotion agreements and through out-licensing partnerships. Dexcel markets its products primarily to drug wholesalers, retail drug chains, distributors, sick funds and government agencies.
Genepharm Australasia is an Australian owned and Australian managed enterprise built on a sustainable business platform of leading products, best people and cost efficient infrastructure. Genepharm's goal is to continue to build a valuable business for all stakeholders, be they shareholders, employees, customers or business partners. Genepharm's focus is to establish a business with a diversified health care offering that is clearly focused on target customer segments. Genepharm has an infrastructure and diversified business model that will enable the business to expand its product offering and accelerate the achievement of growth targets. The Company views an extended product range as a competitive differentiator that can build stronger customer loyalty and provide earnings stability for the business. Genepharm's sales channel is strongly positioned to realise incremental earnings from the development of an extended range of healthcare products that will also deliver sales growth for Australian pharmacists. Genepharm is well positioned for the 2007 financial year with a sound sales and marketing strategy that will uniquely position the company with Australian pharmacists. The four key elements of that strategy are built around the company's core product development infrastructure and are based on a commercial relationship with pharmacy that will provide a competitive and sustainable model of value, service, customer care and equity. The strong market outlook for generic pharmaceuticals is continuing with compounded growth of over 20% per annum expected for the next three to five years. The market for generic pharmaceuticals is expected to grow to around $1 billion in 2006 to over $2 billion by 2009, a figure which includes the impact of cost saving measures announced by the federal government. The key growth drivers are the expirations of many of the top 100 PBS drugs between now and 2008; increasing government and public support for generic pharmaceuticals; and an ageing, more drug reliant population.
IntelGenx Technologies Corp. is a Canada-based drug delivery company that focuses on the development of orally administered drug delivery systems based on its oral drug delivery technologies. The Company has three delivery platform technologies that it uses to develop products: a Tri-Layer Tablet technology, a Quick Release wafer technology and a Mucoadhesive Tablet technology. Its Tri-layer platform technology allows for the development of oral controlled release products. The Quick Release Wafer technology allows for the instant delivery of pharmaceuticals to the oral cavity. The Mucoadhesive Tablet allows for the controlled release of active substances to the oral mucosa. The Company's product portfolio includes INT0001/2004, INT0003/2005, INT0004/2006, INT0005/2005, INT0006/2005, INT0010/2006, INT0011/2007, INT0007/2006 and INT0008/2007. (Source: 10KSB)
Pharmascience researches, develops, manufactures and markets generic and innovative products for both prescription and over-the-counter sale. We are generators -- the first pharmaceutical company in Canada to integrate all these capabilities under one umbrella. This approach uniquely qualifies us to meet the needs of pharmacists, physicians and patients for a truly comprehensive array of significant and affordable drugs. It also makes us an advantageous partner in a broad spectrum of joint developments, as many pharmaceutical firms and universities at home and abroad have discovered. Pharmascience is one of Canada's fastest growing pharmaceutical companies. We started out in 1983 with two innovative drugs, 15 generic ones, and 10 types of vitamins. Today we produce more than 330 quality brand-name and generic products which are sold in over 30 countries around the world. Our in-house capabilities have grown significantly, as well. More than 90 per cent of our products are manufactured in-house and we have established our own pilot plant for formulation development.
The Intercare Group PLC (www.intercareplc.co.uk) is an international pharmaceutical manufacturing and distribution business that also provides outsourced services to the pharmaceutical industry. The company has two divisions, Pharmaceutical Manufacturing and Pharmaceutical Distribution that operate throughout the United Kingdom and continental Europe, serving the global pharmaceutical market. Intercare operates six manufacturing facilities in the U.K., Belgium and France.
Aurobindo Pharma was born of a vision. Founded in 1986 by Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed set of professionals, the company became a public venture in 1992. It commenced operations in 1988-89 with a single unit manufacturing semi synthetic penicillins (SSPs) at Pondicherry. Aurobindo Pharma had gone public in 1995 by listing its shares in various stock exchanges in the country. The company is the market leader in semi-synthetic penicillin drugs. It has a presence in key therapeutic segments like SSPs, cephalosporins, antivirals, CNS, cardio-vascular, gastroenterology, etc. Over the years, the Aurobindo Pharma has evolved into a knowledge driven company. It is R&D focused, has a multi-product portfolio with multi-country manufacturing facilities, and is becoming a marketing conglomerate across the world. Aurobindo Pharma created a name for itself in the manufacture of bulk actives, its area of core competence. After ensuring a firm foundation of cost effective production capabilities and a clutch of loyal customers, the company has entered the high margin speciality generic formulations segment, with a global marketing network. The formulation business is systematically organised with a divisional structure, and has a focused team for each key international market. Aurobindo believes in gaining volume and market share in every business/segment it enters. Aurobindo has invested significant resources in building a mega infrastructure for APIs and formulations to emerge as a vertically integrated pharmaceutical company. Aurobindo's five units for APIs and four units for formulations are designed for the regulated markets. Aurobindo is one of the most reputed sources of Active Pharmaceutical Ingredient in India.
Aspen Pharmacare markets a broad range of ethical products. These products of original research include a number of well established brands. Aspen Pharmacare's ethical business is a leader in the categories of female healthcare, tranquillisers and hypnotics and cardiovascular medicines. A number of co-marketing agreements have been concluded with multinational companies in terms of which Aspen Pharmacare distributes leading ethical products. Aspen Pharmacare is the leading supplier of generic medicines to the private and public sectors. This leadership position has been achieved by the broad range of quality pharmaceuticals the Group is able to supply at affordable prices. The introduction of new legislation in South Africa compelling generic substitution is expected to lead to an increase in the use of generic medicines. The generic product range is the core of the Group's public sector business which is serviced by the supply of state tenders, public sector hospitals and parastatal institutions. Over the counter (OTC) products are marketed exclusively through pharmacies. Increasing trends in self-medication make this a focus area. Aspen Pharmacare has built particular strength in the niche natural product sector. Another area of emphasis is in lifestyle intervention products which provide a greater sense of "well-being" for users. The fast moving consumer goods (FMCG) division markets a number of well-known and trusted household brands, which are found on the shelves of hypermarkets, supermarkets and cash and carry outlets. Aspen Pharmacare has entered into an agreement with Tibbett and Britten ("T&B") for the provision of its total distribution requirements. It is expected that the change to T&B, one of the world's leaders in supply chain management, will lead to an improvement in efficiencies and resultant cost savings. There are two pharmaceutical manufacturing plants within Aspen Pharmacare. Aspen Pharmacare Lennon, based in Port Elizabeth, is the Group's flagship factory and the heart of its generic business. It manufactures over 20 tons of finished product daily. Aspen Pharmacare East London is the site of the Group's important penicillin plant as well as a specialised aerosol facility. An oral contraceptive facility has also been commissioned at the East London site during the course of the past financial year. This facility manufactures to international quality standards. The new business development ("NBD") unit is responsible for identifying and sourcing new products for Aspen Pharmacare to bring to the market. The Group's pharmaceutical research laboratories ("PRL") are focused on the core activity of developing products which are the first-to-market in the domestic generic sector. PRL has experience in formulating most dosage forms. The Aspen Pharmacare regulatory division has developed sophisticated systems to constantly monitor and prioritise update requirements at an individual product level. These systems also allow for detailed business management of this function in an effort to move staff away from the typical reactive approach and to focus them on the key business needs. This is essential for achieving success given Aspen Pharmacare's large product range. The regulatory department works closely in co-operation with the South African Medicines Control Council ("MCC") in bringing new product registrations to the market.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory